ReviewBiochimie open2016
Dimethyl-Benz(a)anthracene: A mammary carcinogen and a neuroendocrine disruptor.
Review in Biochimie open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 61 citations in OpenAlex.
- Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance.NPJ breast cancer · 2026Review
- Nerolidol-loaded beta-cyclodextrin nanoparticles modulate Nrf-2/Keap1/NF-κB signaling to inhibit DMBA-induced mammary carcinogenesis in Sprague-Dawley rats.Medical oncology (Northwood, London, England) · 2025Article
- Protective effect of purple sweet potatoes (Veterinary world · 2025Article
- Rat Models of Breast Cancer.Advances in experimental medicine and biology · 2025Review
- Black soybean extract inhibits rat mammary carcinogenesis through BRCA1 and TNF-α expression:Open veterinary journal · 2024Article
- Effect ofVeterinary world · 2024Article
- Exposure to brominated flame retardantsFrontiers in endocrinology · 2024Article
- Current Insights in Murine Models for Breast Cancer: Present, Past and Future.Current pharmaceutical design · 2024Review
- Article
- In Vitro and In Vivo Evaluation of the Effectiveness and Safety of Amygdalin as a Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.Journal of mammary gland biology and neoplasia · 2022Review
- Effects of melatonin and metformin in preventing lysosome-induced autophagy and oxidative stress in rat models of carcinogenesis and the impact of high-fat diet.Scientific reports · 2022Article
- Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.International journal of molecular sciences · 2021Article
- Ameliorative effects of colostrum against DMBA hepatotoxicity in rats.Saudi journal of biological sciences · 2021Article
- Cytotoxic T cells response with decreased CD4/CD8 ratio during mammary tumors inhibition in rats induced by non-contact electric fields.F1000Research · 2021Article
- Antitumour Property ofBreast cancer : basic and clinical research · 2020Article
- Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research.GeroScience · 2019Review
- Effect of Genistein Supplementation on the Progression of Neoplasms and the Level of the Modified Nucleosides in Rats With Mammary Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycyclic Aromatic Hydrocarbons (PAHs) are potent carcinogens. Among these, dimethylbenz(a)anthracene (DMBA) is well known for its capacity to induce mammary carcinomas in female Sprague-Dawley (SD) rats. Ovariectomy suppresses the susceptibility of this model to DMBA, thus suggesting that the inducible action of the carcinogen depends on ovarian hormones. The promotion of DMBA-induced adenocarcinoma is accompanied by a series of neuroendocrine disruptions of both Hypothalamo-Pituitary-Gonadal (HPG) and Hypothalamo-Pituitary-Adrenal (HPA) axes and of the secretion of melatonin during the latency period of 2 months that precedes the occurrence of the first mammary tumor. The present review analyses the various neuroendocrine disruptions that occur along the HPG and the HPA axes, and the marked inhibitory effect of the carcinogen on melatonin secretion. The possible relationships between the neuroendocrine disruptions, which essentially consist in an increased pre-ovulatory secretion of 17β-estradiol and prolactin, associated with a marked reduction of melatonin secretion, and the decrease in gene expression of the receptors for aryl-hydrocarbons receptor (AhR) and 17β-estradiol (ERα; ERβ) are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.